Research advancement of non-invasive urinary biomarkers associated with IgA nephropathy

doi:10.3877/cma.j.issn.2095-3216.2015.02.009

Abstract

Abstract:

IgA nephropathy (IgAN) is the most common primary glomerular disease. It′s of very important economic and academic value to find non-invasive biomarkers that can be used in the diagnosis, assessment, and prognosis of IgA nephropathy. In recent five years, the research on non-invasive urinary biomarkers associated with IgAN has made a remarkable progress, especially in podocytes, complement components, RAS-related proteins, and miRNAs.

Key words: IgA nephropathy, Biomarkers

Nannan Wang, Ru Bu, Guangyan Cai, Xiangmei Chen. Research advancement of non-invasive urinary biomarkers associated with IgA nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(02): 97-101.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2015.02.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2015/V04/I02/97

Figures/Tables 1

References 34

[1]	Xie J, Chen N. Primary glomerulonephritis in mainland China: an overview [J]. Contrib Nephrol, 2013, 181: 1-11.
[2]	Xu L, Yang HC, Hao CM, et al. Podocyte number predicts progression of proteinuria in IgA nephropathy [J]. Mod Pathol, 2010, 23(9): 1241-1250.
[3]	Nielsen JS, Mcnagny KM. The role of podocalyxin in health and disease [J]. J Am Soc Nephrol, 2009, 20(8): 1669-1676.
[4]	Hara M, Yanagihara T, Hirayama Y, et al. Podocyte membrane vesicles in urine originate from tip vesiculation of podocyte microvilli [J]. Hum pathol, 2010, 41(9): 1265-1275.
[5]	Asao R, Asanuma K, Kodama F, et al. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy [J]. Clin J Am Soc Nephrol, 2012, 7(9): 1385-1393.
[6]	Asanuma K, Campbell KN, Kim K, et al. Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes [J]. Proc Natl Acad Sci USA, 2007, 104(24): 10134-10139.
[7]	Kodama F, Asanuma K, Takagi M, et al. Translocation of dendrin to the podocyte nucleus in acute glomerular injury in patients with IgA nephropathy [J]. Nephrol Dial Transplant, 2013, 28(7): 1762-1772.
[8]	Coppo R, Amore A, Peruzzi L, et al. Innate immunity and IgA nephropathy [J]. J Nephrol, 2010, 23(6): 626-632.
[9]	Liu LL, Jiang Y, Wang LN, et al. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy [J]. Clin Exp Immunol, 2012, 169(2): 148-55.
[10]	Onda K, Ohsawa I, Ohi H, et al. Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function [J]. BMC Nephrol, 2011, 12: 64.
[11]	Zhang JJ, Jiang L, Liu G, et al. Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity [J]. Scand J Immunol, 2009, 69(5): 457-464.
[12]	Liu L, Zhang Y, Duan X, et al. C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy [J]. J Clin Immunol, 2014, 34(2): 224-232.
[13]	Miyake-Ogawa C, Miyazaki M, Abe K, et al. Tissue-specific expression of renin-angiotensin system components in IgA nephropathy [J]. Am J Nephrol, 2005, 25(1): 1-12.
[14]	Nishiyama A, Konishi Y, Ohashi N, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy [J]. Nephrol Dial Transplant, 2011, 26(1): 170-177.
[15]	Kim YG, Song SB, Lee SH, et al. Urinary angiotensinogen as a predictive marker in patients with immunoglobulin A nephropathy [J]. Clin Exp Nephrol, 2011, 15(5): 720-726.
[16]	Rocchetti MT1, Tamma G, Lasorsa D, et al. Altered urinary excretion of aquaporin 2 in IgA nephropathy [J]. Eur J Endocrinol, 2011, 165(4): 657-664.
[17]	Lu X, Li M, Zhou L, et al. Urinary serum- and glucocorticoid-inducible kinase SGK1 reflects renal injury in patients with immunoglobulin A nephropathy [J]. Nephrology (Carlton), 2014, 19(6): 307-317.
[18]	Stangou M, Papagianni A, Bantis C, et al. Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine [J]. Clin Nephrol, 2013, 80(3): 203-210.
[19]	Ranieri E, Gesualdo L, Petrarulo F, et al. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy [J]. Kidney Int, 1996, 50(6): 1990-2001.
[20]	Torres DD, Rossini M, Manno C, et al. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy [J]. Kidney Int, 2008, 73(3): 327-333.
[21]	Stangou M, Alexopoulos E, Papagianni A, et al. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy [J]. Nephrology (Carlton), 2009, 14(6): 613-620.
[22]	Han WK, Bailly V, Abichandani R, et al. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury [J]. Kidney Int, 2002, 62(1): 237-244.
[23]	van Timmeren MM, van den Heuvel MC, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease [J]. J Pathol, 2007, 212(2): 209-217.
[24]	Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans [J]. Clin Transl Sci, 2008, 1(3): 200-208.
[25]	Xu PC, Zhang JJ, Chen M, et al. Urinary kidney injury molecule-1 in patients with IgA nephropathy is closely associated with disease severity [J]. Nephrol Dial Transplant, 2011, 26(10): 3229-3236.
[26]	Peters HP, Waanders F, Meijer E, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy [J]. Nephrol Dial Transplant, 2011, 26(11): 3581-3588.
[27]	Wu J, Wang N, Wang J, et al. Identification of a uromodulin fragment for diagnosis of IgA nephropathy [J]. Rapid Commun Mass Spectrom, 2010, 24(14): 1971-1978.
[28]	Obara T1, Mizoguchi S, Shimozuru Y, et al. The complex of immunoglobulin A and uromodulin as a diagnostic marker for immunoglobulin A nephropathy [J]. Clin Exp Nephrol, 2012, 16(5): 713-721.
[29]	Rocchetti MT, Papale M, d′Apollo AM, et al. Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy [J]. Clin J Am Soc Nephrol, 2013, 8(7): 1115-1125.
[30]	Surin B, Sachon E, Rougier JP, et al. LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy [J]. Proteomics, 2013, 13(1): 142-152.
[31]	Wang G, Kwan BC, Lai FM, et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy [J]. Dis Markers, 2010, 28(2): 79-86.
[32]	Wang G, Kwan BC, Lai FM, et al. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy [J]. Dis Markers, 2011, 30(4): 171-179.
[33]	Szeto CC, Ching-Ha KB, Ka-Bik L, et al. Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases [J]. Dis Markers, 2012, 33(3): 137-144.
[34]	Gonzales PA, Pisitkun T, Hoffert JD, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes [J]. J Am Soc Nephrol, 2009, 20(2): 363-379.

标志物		来源	表达趋势	能否提示诊断	能否提示预后	与临床指标的相关性
足细胞成分及其标志物		?	?	?	?	?
?	Podocalyxin^[3,4,5]	尿液	↑	－	－	与急性毛细血管外病变正相关
?	Dendrin^[6,7]	尿沉渣	↑	－	－	与Scr负相关，与eGFR正相关
补体蛋白成分		?	?	?	?	?
?	甘露糖结合凝集素^[9]	尿上清液	↑	－	√	与Scr、尿蛋白和病理评分正相关，与eGFR负相关
?	膜攻击复合物^[10,11]	尿液	↑	－	－	与Scr、尿蛋白、间质纤维化和肾小球硬化正相关
?	补体因子H^[10,11]	尿液	↑	－	－	与Scr、尿蛋白、间质纤维化和肾小球硬化正相关
?	C3a和C5a^[12]	尿液	↑	－	－	与Scr、尿蛋白和病理分级正相关
RAS相关蛋白		?	?	?	?	?
?	尿血管紧张素原^[14,15]	尿液	↑	－	－	与收缩压、尿蛋白/肌酐、滤过分数和肾组织血管紧张素Ⅱ正相关
?	尿液水通道蛋白2^[16]	尿上清液	↑	－	－	与高血压相关
?	血清和糖皮质激素诱导的蛋白激酶－1^[17]	尿液	↑	－	－	与Scr、尿蛋白、血尿酸和eGFR正相关
细胞因子		?	?	?	?	?
?	单核细胞趋化蛋白－1^[18]	尿上清液	↑	－	－	与毛细血管内增生正相关
?	IL－17^[18]	尿上清液	↑	－	－	与毛细血管内增生正相关
?	INF－γ^[18]	尿上清液	↑	－	－	与毛细血管内增生正相关
?	IL－10^[18]	尿上清液	↑	－	－	与毛细血管内增生正相关
?	IL－1β^[18]	尿上清液	↑	－	－	与Scr、毛细血管内增生和肾小球硬化正相关
?	表皮细胞生长因子^[18]	尿上清液	↓	－	－	与Scr和肾小球硬化负相关
?	IL－6^{[18,19,20,21]}	尿上清液	↑	－	√	与毛细血管内增生、肾小球硬化正相关
miRNAs		?	?	?	?	?
?	miR－200a^[31]	尿沉渣	↓	－	－	与蛋白尿负相关
?	miR－200b^[31]	尿沉渣	↓	－	√	与蛋白尿负相关，与GFR正相关
?	miR－429^[31]	尿沉渣	↓	－	－	与蛋白尿和肾小球硬化负相关，与GFR正相关
?	miR－146a	尿沉渣	↑	－	－	与蛋白尿正相关
?	miR－155^[32]	尿沉渣	↑	－	－	与蛋白尿正相关
?	miR－17^[33]	尿沉渣	↑	－	－	与GFR正相关
其他		?	?	?	?	?
?	肾损伤分子－1^[25,26]	尿上清液	↑	－	√	与Scr、尿蛋白正相关
?	LG3^[29,30]	尿上清液	↓	－	√	与Scr、尿蛋白正相关
?	游离κ轻链^[29,30]	尿上清液	↓	－	√	与蛋白尿、Scr和病理评分负相关
?	尿调节素^[27]	尿上清液	↑	√	－	－
?	IgA－尿调节素复合物^[28]	尿液	↑	√	－	－

标志物		来源	表达趋势	能否提示诊断	能否提示预后	与临床指标的相关性
足细胞成分及其标志物		?	?	?	?	?
?	Podocalyxin^[3,4,5]	尿液	↑	－	－	与急性毛细血管外病变正相关
?	Dendrin^[6,7]	尿沉渣	↑	－	－	与Scr负相关，与eGFR正相关
补体蛋白成分		?	?	?	?	?
?	甘露糖结合凝集素^[9]	尿上清液	↑	－	√	与Scr、尿蛋白和病理评分正相关，与eGFR负相关
?	膜攻击复合物^[10,11]	尿液	↑	－	－	与Scr、尿蛋白、间质纤维化和肾小球硬化正相关
?	补体因子H^[10,11]	尿液	↑	－	－	与Scr、尿蛋白、间质纤维化和肾小球硬化正相关
?	C3a和C5a^[12]	尿液	↑	－	－	与Scr、尿蛋白和病理分级正相关
RAS相关蛋白		?	?	?	?	?
?	尿血管紧张素原^[14,15]	尿液	↑	－	－	与收缩压、尿蛋白/肌酐、滤过分数和肾组织血管紧张素Ⅱ正相关
?	尿液水通道蛋白2^[16]	尿上清液	↑	－	－	与高血压相关
?	血清和糖皮质激素诱导的蛋白激酶－1^[17]	尿液	↑	－	－	与Scr、尿蛋白、血尿酸和eGFR正相关
细胞因子		?	?	?	?	?
?	单核细胞趋化蛋白－1^[18]	尿上清液	↑	－	－	与毛细血管内增生正相关
?	IL－17^[18]	尿上清液	↑	－	－	与毛细血管内增生正相关
?	INF－γ^[18]	尿上清液	↑	－	－	与毛细血管内增生正相关
?	IL－10^[18]	尿上清液	↑	－	－	与毛细血管内增生正相关
?	IL－1β^[18]	尿上清液	↑	－	－	与Scr、毛细血管内增生和肾小球硬化正相关
?	表皮细胞生长因子^[18]	尿上清液	↓	－	－	与Scr和肾小球硬化负相关
?	IL－6^{[18,19,20,21]}	尿上清液	↑	－	√	与毛细血管内增生、肾小球硬化正相关
miRNAs		?	?	?	?	?
?	miR－200a^[31]	尿沉渣	↓	－	－	与蛋白尿负相关
?	miR－200b^[31]	尿沉渣	↓	－	√	与蛋白尿负相关，与GFR正相关
?	miR－429^[31]	尿沉渣	↓	－	－	与蛋白尿和肾小球硬化负相关，与GFR正相关
?	miR－146a	尿沉渣	↑	－	－	与蛋白尿正相关
?	miR－155^[32]	尿沉渣	↑	－	－	与蛋白尿正相关
?	miR－17^[33]	尿沉渣	↑	－	－	与GFR正相关
其他		?	?	?	?	?
?	肾损伤分子－1^[25,26]	尿上清液	↑	－	√	与Scr、尿蛋白正相关
?	LG3^[29,30]	尿上清液	↓	－	√	与Scr、尿蛋白正相关
?	游离κ轻链^[29,30]	尿上清液	↓	－	√	与蛋白尿、Scr和病理评分负相关
?	尿调节素^[27]	尿上清液	↑	√	－	－
?	IgA－尿调节素复合物^[28]	尿液	↑	√	－	－

Please choose a citation manager

Content to export